Elevated eIF3h has been confirmed in 18% of breast cancer, 30% of prostate cancer (Nupponen et al., 1999) and 50% of hepatocellular carcinoma (Zhu et al., 2016). Here, EIF3H is linked to hepatocellular carcinoma.